FOXA1: a Promising Prognostic Marker in Breast Cancer

  • Hu, Qing ;
  • Luo, Zhou ;
  • Xu, Tao ;
  • Zhang, Jun-Ying ;
  • Zhu, Ying ;
  • Chen, Wei-Xian ;
  • Zhong, Shan-Liang ;
  • Zhao, Jian-Hua ;
  • Tang, Jin-Hai
  • Published : 2014.01.15


Accurate diagnosis and proper monitoring of cancer patients remain important obstacles for successful cancer treatment. The search for cancer biomarkers can aid in more accurate prediction of clinical outcome and may also reveal novel predictive factors and therapeutic targets. One such prognostic marker seems to be FOXA1. Many studies have shown that FOXA1 is strongly expressed in a vast majority of cancers, including breast cancer, in which high expression is associated with a good prognosis. In this review, we summarize the role of this transcription factor in the development and prognosis of breast cancer in the hope of providing insights into utility of FOXA1 as a novel biomarker.


FOXA1;prognosis;biomarker;breast cancer;systematic review


  1. Nakshatri H, Badve S (2007). FOXA1 as a therapeutic target for breast cancer. Expert Opin Ther Targets, 11, 507-14.
  2. Kouros-Mehr H, Slorach EM, Sternlicht MD, et al (2006). GATA-3 maintains the differentiation of the luminal cell fate in the mammary gland. Cell, 127, 1041-55.
  3. Liu N, Niu Y, Wang SL, et al (2010). Diagnostic and prognostic sign ificance of FOXA1 expression in molecular subtypes of breast invasive ductal carcinomas. Zhonghua Yi Xue Za Zhi, 90, 1403-7.
  4. Mehta RJ, Jain RK, Leung S, et al (2012). FOXA1 is an independent prognostic marker for ER-positive breast cancer. Breast Cancer Res Treat, 131, 881-90.
  5. Perou CM, Sorlie T, Eisen MB, et al (2000). Molecular portraits of human breast tumours. Nature, 406, 747-52.
  6. Sircoulomb F, Bekhouche I, Finetti P, et al (2010). Genome profiling of ERBB2-amplified breast cancers. BMC Cancer, 10, 539.
  7. Sorlie T, Perou CM, Tibshirani R, et al (2001). Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A, 98, 10869-10874.
  8. Thorat MA, Marchio C, Morimiya A, et al (2007). Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis. J Clin Pathol, 61, 327-32..
  9. Wolf I, Bose S, Williamson EA, et al (2007). FOXA1: Growth inhibitor and a favorable prognostic factor in human breast cancer. Int J Cancer, 120, 1013-22.
  10. Yamaguchi N, Ito E, Azuma S, et al (2008). FoxA1 as a lineagespecific oncogene in luminal type breast cancer. Biochem Biophys Res Commun, 365, 711-7.
  11. Yerushalmi R, Woods R, Ravdin PM, et al (2010). Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol, 11, 174-83.
  12. Habashy HO, Powe DG, Rakha EA, et al (2008). Forkhead-box A1 (FOXA1) expression in breast cancer and its prognostic significance. Eur J Cancer, 44,1541-51.
  13. Costa RH, Grayson DR, Darnell JE, et al (1989). Multiple hepatocyte-enriched nuclear factors function in the regulation of transthyretin and alpha 1-antitrypsin genes. Mol Cell Biol, 9, 1415-25.
  14. Desantis C, Ma J, Bryan L, et al (2013). Breast cancer statistics. CA Cancer J Clin, 9, 69-90.
  15. Goldhirsch A, Ingle JN, Gelber RD, et al (2009). Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol, 20, 1319-29.
  16. Hayes DF (2005). Prognostic and predictive factors revisited. Breast, 14, 493-9.
  17. Hisamatsu Y, Tokunaga E, Yamashita N, et al (2012). Impact of FOXA1 expression on the prognosis of patients with hormone receptor-positive breast cancer. Ann Surg Oncol, 19, 1145-52.
  18. Hurtado A, Holmes KA, Ross-Innes CS, et al (2011). FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nat Genet, 43, 27-33.
  19. Ijichi N, Shigekawa T, Ikeda K, et al (2012). Association of double-positive FOXA1 and FOXP1 immunoreactivities with favorable prognosis of tamoxifen-treated breast cancer patients. Horm Cancer, 3, 147-59.
  20. Kawase M, Toyama T, Takahashi S, et al (2013). FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer. Breast Cancer. [Epub ahead of print]
  21. Kim C, Paik S 2010. Gene-expression-based prognostic assays for breast cancer. Nat Rev Clin Oncol, 7, 340-7.
  22. Knight WA, Osborne CK, Yochmowitz MG, et al (1980). Steroid hormone receptors in the management of human breast cancer. Ann Clin Res, 12, 202-7.
  23. Badve S, Turbin D, Thorat MA, et al (2007). FOXA1 expression in breast cancer--correlation with luminal subtype A and survival. Clin Cancer Res, 13, 4415-21.
  24. Ademuyiwa FO, Thorat MA, Jain RK, et al (2010). Expression of Forkhead-box protein A1, a marker of luminal A type breast cancer, parallels low Oncotype DX 21-gene recurrence scores. Mod Pathol, 23, 270-5.
  25. Albergaria A, Paredes J, Sousa B, et al (2009). Expression of FOXA1 and GATA-3 in breast cancer: the prognostic significance in hormone receptor-negative tumours. Breast Cancer Res, 11, R40.
  26. Badve S, Nakshatri H (2009). Oestrogen-receptor-positive breast cancer: towards bridging histopathological and molecular classifications. J Clin Pathol, 62, 6-12.
  27. Beck S, Sommer P, dos Santos Silva E, et al (1999). Hepatocyte nuclear factor 3 (winged helix domain) activates trefoil factor gene TFF1 through a binding motif adjacent to the TATAA box. DNA Cell Biol, 18, 157-64.
  28. Bernardo GM, Keri RA (2012). FOXA1: a transcription factor with parallel functions in development and cancer. Biosci Rep, 32, 113-30.
  29. Bernardo GM, Lozada KL, Miedler JD, et al (2010). FOXA1 is an essential determinant of ERalpha expression and mammary ductal morphogenesis. Development, 137, 2045-54.
  30. Carroll JS, Brown M (2006). Estrogen receptor target gene: an evolving concept. Mol Endocrinol, 20, 1707-14.

Cited by

  1. Analysis of Indoleamine 2-3 Dioxygenase (IDO) and EGFR Co-expression in Breast Cancer Tissue by Immunohistochemistry vol.15, pp.14, 2014,
  2. Systemic Analysis on Risk Factors for Breast Cancer Related Lymphedema vol.15, pp.16, 2014,
  3. Legumain Protein as a Potential Predictive Biomarker for Asian Patients with Breast Carcinoma vol.15, pp.24, 2015,
  4. Ultrasonographic Features of Triple-Negative Breast Cancer: a Comparison with Other Breast Cancer Subtypes vol.16, pp.8, 2015,
  5. Clinicopathological significance of forkhead box protein A1 in breast cancer: A meta-analysis vol.11, pp.6, 2016,
  6. Foxa1 is essential for mammary duct formation vol.54, pp.5, 2016,
  7. miR-204 regulates the biological behavior of breast cancer MCF-7 cells by directly targeting FOXA1 vol.38, pp.1, 2017,
  8. The prognostic relevance of FOXA1 and Nestin expression in breast cancer metastases: a retrospective study of 164 cases during a 10-year period (2004–2014) vol.19, pp.1, 2019,